A Phase 4 interventional study of COPEGUS and peginterferon alfa-2a [Pegasys] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 20 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-03.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 175 studies testing ribavirin in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Ribavirin · Hepatitis C, Chronic.
Among the 175 studies testing ribavirin in Hepatitis C, Chronic, this one is the 119th largest by enrollment of the 174 interventional ones that give a count, is one of 8 that started in 2009, is one of 55 in phase 4, and was the 98th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 175 studies testing ribavirin in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
175 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 43 · Phase 3 66 · Phase 4 55
First in 1997; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 107 across the 174 interventional studies. Of the 159 that completed or were terminated, 87 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 175 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 45th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2009, is one of 29 in phase 4, and was the 33rd registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 175 studies testing ribavirin in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, multi-center study will evaluate the safety and tolerability and the effect on viral activity of a combined PEGASYS and COPEGUS extended therapy in patients with chronic hepatitis C with genotype 1, 2 and 3. Patients who completed 48 weeks (genotype 1) or 24 weeks (genotype 2 and 3) of standard treatment with PEGASYS and COPEGUS and were identified as slow virological responders will be enrolled in this study in order to receive additional 24 weeks of treatment. PEGASYS 180 micrograms will be administered sc once weekly and COPEGUS will be administered as 800 mg, or 1000-1200 mg daily oral doses. The anticipated time on study treatment is 24 weeks. The target sample size is 50-150 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: COPEGUS · Drug: peginterferon alfa-2a [Pegasys]
COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
PEGASYS 180 micrograms sc once weekly for 24 weeks
End of Treatment Response Rate at Week 72 in Genotype 1
End of treatment response rate at Week 72 was reported for genotype 1.
Time frame: Week 72
End of Treatment Response in Genotype 2 and 3
End of treatment response rate at Week 48 was reported for genotype 2 and 3.
Time frame: Week 48
Sustained Viral Response (SVR) Rates in CHC Genotype 1
Sustained Viral Response, undetectable HCV-RNA 24 weeks after the end of treatment for genotype 1.
Time frame: Week 96
SVR Rates in Genotype 2 and 3.
Sustained Viral Response, undetectable HCV-RNA 24 weeks after the end of treatment for genotype 2 and 3.
Time frame: Week 72
Percentage of Participants With Adverse Event (AE)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Week 96
Participants from Study NCT01429792 with genotype 1 Chronic Hepatitis C (CHC) and were 'Slow Responders' were eligible to enroll in this treatment extension study. Participants from Study NCT01429792 with genotype 2 and 3 CHC and were non-Rapid Virologic Response (RVR) were eligible to enroll in this treatment extension study.
| Milestone | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Started | 59 |
| Completed | 47 |
| Not completed | 12 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Positive hcv-rna at week 48 | 1 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrew due to other reasons | 3 |
| Withdrew: Unknown disposition | 1 |
End of treatment response rate at Week 72 was reported for genotype 1.
| Percentage of Participants | CHC Genotype 1 |
|---|---|
| End of Treatment Response Rate at Week 72 in Genotype 1 | 68.2 |
End of treatment response rate at Week 48 was reported for genotype 2 and 3.
| Percentage of Participants | CHC Genotype 2 and 3 |
|---|---|
| End of Treatment Response in Genotype 2 and 3 | 66.7 |
Sustained Viral Response, undetectable HCV-RNA 24 weeks after the end of treatment for genotype 1.
| Percentage of participants | CHC Genotype 1 |
|---|---|
| Sustained Viral Response (SVR) Rates in CHC Genotype 1 | 46.5 (31.2 to 62.3) |
Sustained Viral Response, undetectable HCV-RNA 24 weeks after the end of treatment for genotype 2 and 3.
| Percentage of participants | CHC Genotype 2 and 3 |
|---|---|
| SVR Rates in Genotype 2 and 3. | 60.0 (32.3 to 83.7) |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Percentage of Participants | Pegylated Interferon (Peginterferon) Alfa2a |
|---|---|
| Percentage of Participants With Adverse Event (AE) | 40.7 |
Collected over Baseline to Week 96. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegylated Interferon Alfa2a (Peginterferon) | — | 5/59 (8.5%) | 14/59 (23.7%) |
| Event | Pegylated Interferon Alfa2a (Peginterferon) |
|---|---|
| PyrexiaGeneral disorders | 1/59 |
| Anal AbscessInfections and infestations | 1/59 |
| AnaesthesiaNervous system disorders | 1/59 |
| Cerebrovascular accidentNervous system disorders | 1/59 |
| Pregnancy of partnerSocial circumstances | 1/59 |
| Event | Pegylated Interferon Alfa2a (Peginterferon) |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 12/59 |
| NeutropeniaBlood and lymphatic system disorders | 4/59 |
All enrolled participants were included in the baseline population.
| Age, Continuous(Years) | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Mean | 47.9 ± 10.4 |
| Sex: Female, Male(Participants) | Pegylated Interferon (Peginterferon) Alfa-2a |
|---|---|
| Female | 34 |
| Male | 25 |
The record gives a start of Dec 2009, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2017, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ribavirin · Peginterferon alfa-2a